{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:36:41Z","timestamp":1777379801484,"version":"3.51.4"},"reference-count":59,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V03 (UK MRC's Global Effort on COVID-19)"],"award-info":[{"award-number":["MR\/V03 (UK MRC's Global Effort on COVID-19)"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections","award":["NIHR200907"],"award-info":[{"award-number":["NIHR200907"]}]},{"name":"NIHR Global Health Research Group on Brain Infections","award":["No. 17\/63\/110"],"award-info":[{"award-number":["No. 17\/63\/110"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["ACF-2020-07-003"],"award-info":[{"award-number":["ACF-2020-07-003"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2022,5,13]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate features of Guillain-Barr\u00e9 syndrome (GBS) following SARS-CoV-2 vaccines and evaluate for a causal link between the two.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We captured cases of GBS after SARS-CoV-2 vaccination through a national, open-access, online surveillance system. For each case, the certainty of GBS was graded using the Brighton criteria, and the relationship to the vaccine was examined using modified WHO Causality Assessment criteria. We compared age distribution of cases with that of prepandemic GBS cases and clinical features with the International GBS Outcome Study (IGOS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between 1 January and 30 June 2021, we received 67 reports of GBS following the ChAdOx1 vaccine (65 first doses) and three reports following the BNT162b2 vaccine (all first doses). The causal association with the vaccine was classified as probable for 56 (80%, all ChAdOx1), possible for 12 (17%, 10 ChAdOx1) and unlikely for two (3%, 1 ChAdOx1). A greater proportion of cases occurred in the 50\u201359 age group in comparison with prepandemic GBS. Most common clinical variants were sensorimotor GBS (n=55; 79%) and facial diplegia with paraesthesias (n=10; 14%). 10% (n=7\/69) of patients reported an antecedent infection, compared with 77% (n=502\/652) of the IGOS cohort (p&lt;0.00001). Facial weakness (63% (n=44\/70) vs 36% (n=220\/620); p&lt;0.00001) and sensory dysfunction (93% (n=63\/68) vs 69% (n=408\/588); p=0.00005) were more common but disease severity and outcomes were similar to the IGOS study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>Most reports of GBS followed the first dose of ChAdOx1 vaccine. While our study cannot confirm or refute causation, this observation, together with the absence of alternative aetiologies, different than expected age distribution and the presence of unusual clinical features support a causal link. Clinicians and surveillance bodies should remain vigilant to the possibility of this very rare adverse event and its atypical variants.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2022-000309","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:11:28Z","timestamp":1657631488000},"page":"e000309","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Guillain-Barr\u00e9 syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study"],"prefix":"10.1136","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4661-8407","authenticated-orcid":false,"given":"Arina A","family":"Tamborska","sequence":"first","affiliation":[{"name":"National Institute for Health Research Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK"},{"name":"Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagteshwar","family":"Singh","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK"},{"name":"Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-6926","authenticated-orcid":false,"given":"Sonja E","family":"Leonhard","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5821-1685","authenticated-orcid":false,"given":"Eva Maria","family":"Hodel","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK"},{"name":"Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Stowe","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Watson-Fargie","sequence":"additional","affiliation":[{"name":"Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-1543","authenticated-orcid":false,"given":"Andreas C","family":"Themistocleous","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurociences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Roelofs","sequence":"additional","affiliation":[{"name":"Neurosciences Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-2706","authenticated-orcid":false,"given":"Kathryn","family":"Brennan","sequence":"additional","affiliation":[{"name":"Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Morrice","sequence":"additional","affiliation":[{"name":"GAIN (Guillain-Barr\u00e9 & Associated Inflammatory Neuropathies) Charity, Sleaford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedict D","family":"Michael","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK"},{"name":"Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-2458","authenticated-orcid":false,"given":"Bart C","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Neurology and Immunology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McDonald","sequence":"additional","affiliation":[{"name":"NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-6547","authenticated-orcid":false,"given":"Tom","family":"Solomon","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK"},{"name":"Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"2025072811393103000_4.2.e000309.1","unstructured":"GOV.UK . Vaccinations in the UK, 2021. Available: https:\/\/coronavirus.data.gov.uk\/details\/vaccinations"},{"key":"2025072811393103000_4.2.e000309.2","unstructured":"GOV.UK . COVID-19 vaccination first phase priority groups, 2021. Available: https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccination-care-home-and-healthcare-settings-posters\/covid-19-vaccination-first-phase-priority-groups"},{"key":"2025072811393103000_4.2.e000309.3","doi-asserted-by":"publisher","DOI":"10.1159\/000184748"},{"key":"2025072811393103000_4.2.e000309.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9"},{"key":"2025072811393103000_4.2.e000309.5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain"},{"key":"2025072811393103000_4.2.e000309.6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s41983-021-00310-7","article-title":"Guillain-Barre syndrome in 220 patients with COVID-19","volume":"57","author":"Finsterer","year":"2021","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"2025072811393103000_4.2.e000309.7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/brain\/awaa444","article-title":"COVID-19 vaccine and Guillain-Barr\u00e9 syndrome: let's not leap to associations","volume":"144","author":"Lunn","year":"2021","journal-title":"Brain"},{"key":"2025072811393103000_4.2.e000309.8","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"2025072811393103000_4.2.e000309.9","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.vaccine.2021.03.015","article-title":"Safety monitoring of COVID-19 vaccines - Lessons learned from the 1976 national influenza immunization program about detecting rare vaccine-related severe adverse events in emergency mass-vaccination programs","volume":"39","author":"Kendal","year":"2021","journal-title":"Vaccine"},{"key":"2025072811393103000_4.2.e000309.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-019-00670-y","article-title":"Do vaccines trigger neurological diseases? epidemiological evaluation of vaccination and neurological diseases using examples of multiple sclerosis, Guillain-Barr\u00e9 syndrome and narcolepsy","volume":"34","author":"Stowe","year":"2020","journal-title":"CNS Drugs"},{"key":"2025072811393103000_4.2.e000309.11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.26144","article-title":"Guillain-Barr\u00e9 syndrome variant occurring after SARS-CoV-2 vaccination","volume":"90","author":"Allen","year":"2021","journal-title":"Ann Neurol"},{"key":"2025072811393103000_4.2.e000309.12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 syndrome following ChAdOx1-S\/nCoV-19 vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann Neurol"},{"key":"2025072811393103000_4.2.e000309.13","unstructured":"European Medicines Agency . Meeting highlights from the pharmacovigilance risk assessment Committee (PRAC) 5-8 July 2021, 2021. Available: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-july-2021"},{"key":"2025072811393103000_4.2.e000309.14","unstructured":"European Medicines Agency . COVID-19 vaccine safety update, 2021. Available: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf"},{"key":"2025072811393103000_4.2.e000309.15","unstructured":"U. S. Food and Drug Administration . Coronavirus (COVID-19) update: July 13, 2021, 2021. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-july-13-2021"},{"key":"2025072811393103000_4.2.e000309.16","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7032e4"},{"key":"2025072811393103000_4.2.e000309.17","unstructured":"Association of British Neurologists . RaDAR COVID-19 vaccine, 2021. Available: https:\/\/www.theabn.org\/page\/covid-19_vaccine_radar"},{"key":"2025072811393103000_4.2.e000309.18","unstructured":"Health Research Authority . Guidance for using patient data, 2021. Available: https:\/\/www.hra.nhs.uk\/covid-19-research\/guidance-using-patient-data\/ [Accessed 25 Jan 2022]."},{"key":"2025072811393103000_4.2.e000309.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.003"},{"key":"2025072811393103000_4.2.e000309.20","unstructured":"World Health Organization . Causality assessment of an adverse event following immunization (AEFI). In: Updated user manual for the revised WHO classification. 2nd edition, 2019."},{"key":"2025072811393103000_4.2.e000309.21","unstructured":"Brain Infections Global COVID-Neuro Network . COVID-Vaccine Neuro AE: brain infections global, 2021. Available: https:\/\/braininfectionsglobal.tghn.org\/covid-neuro\/covid-vaccine-neuro-ae\/ [Accessed 25 Jan 2022]."},{"key":"2025072811393103000_4.2.e000309.22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"The Lancet"},{"key":"2025072811393103000_4.2.e000309.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6330-4"},{"key":"2025072811393103000_4.2.e000309.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30221-0"},{"key":"2025072811393103000_4.2.e000309.25","unstructured":"NHS Digital . Hospital episode statistics (Hes), 2021. Available: https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics"},{"key":"2025072811393103000_4.2.e000309.26","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"2025072811393103000_4.2.e000309.27","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy232"},{"key":"2025072811393103000_4.2.e000309.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00467-y"},{"key":"2025072811393103000_4.2.e000309.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92644-2"},{"key":"2025072811393103000_4.2.e000309.30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e07d14"},{"key":"2025072811393103000_4.2.e000309.31","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-326924"},{"key":"2025072811393103000_4.2.e000309.32","unstructured":"The Uppsala Monitoring Centre . The use of the WHO-UMC system for standardised case causality assessment, 2013. Available: https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf"},{"key":"2025072811393103000_4.2.e000309.33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327027"},{"key":"2025072811393103000_4.2.e000309.34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mus.27461","article-title":"Acute-Onset polyradiculoneuropathy after SARS-CoV2 vaccine in the West and North Midlands, United Kingdom","volume":"65","author":"Loo","year":"2022","journal-title":"Muscle Nerve"},{"key":"2025072811393103000_4.2.e000309.35","unstructured":"Medicines and Healthcare products Regulatory Agency . Coronavirus vaccine - weekly summary of Yellow Card reporting; 2021."},{"key":"2025072811393103000_4.2.e000309.36","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440512"},{"key":"2025072811393103000_4.2.e000309.37","unstructured":"GOV.UK . Information for healthcare professionals on Guillain-Barr\u00e9 Syndrome (GBS) following COVID-19 vaccination, 2021. Available: https:\/\/www.gov.uk\/government\/publications\/covid-19-vaccination-guillain-barre-syndrome-information-for-healthcare-professionals\/information-for-healthcare-professionals-on-guillain-barre-syndrome-gbs-following-covid-19-vaccination [Accessed 28 Mar 2022]."},{"key":"2025072811393103000_4.2.e000309.38","unstructured":"Public Health England . Direct and indirect impact of the vaccination programme on COVID-19 infections and mortality, 2021. Available: https:\/\/www.gov.uk\/government\/publications\/phe-monitoring-of-the-effectiveness-of-covid-19-vaccination [Accessed 25 Jan 2022]."},{"key":"2025072811393103000_4.2.e000309.39","unstructured":"The Common Wealth Fund . Deaths and hospitalizations averted by rapid U.S. vaccination Rollout, 2021. Available: https:\/\/www.commonwealthfund.org\/publications\/issue-briefs\/2021\/jul\/deaths-and-hospitalizations-averted-rapid-us-vaccination-rollout [Accessed 25 Jan 2022]."},{"key":"2025072811393103000_4.2.e000309.40","unstructured":"Holder J . Tracking coronavirus vaccinations around the world, 2021. Available: https:\/\/www.nytimes.com\/interactive\/2021\/world\/covid-vaccinations-tracker.html [Accessed 25 Jan 2022]."},{"key":"2025072811393103000_4.2.e000309.41","unstructured":"Mikulic M . Drug manufacturers with the highest number of ordered COVID-19 vaccine doses as of March 2021, 2021. Available: https:\/\/www.statista.com\/statistics\/1195971\/number-of-covid-19-vaccine-doses-by-manufacturer\/"},{"key":"2025072811393103000_4.2.e000309.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105385"},{"key":"2025072811393103000_4.2.e000309.43","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27024"},{"key":"2025072811393103000_4.2.e000309.44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1110"},{"key":"2025072811393103000_4.2.e000309.45","unstructured":"Public Health England . JCVI advises on COVID-19 vaccine for people aged under 40, 2021. Available: https:\/\/www.gov.uk\/government\/news\/jcvi-advises-on-covid-19-vaccine-for-people-aged-under-40"},{"key":"2025072811393103000_4.2.e000309.46","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.577427"},{"key":"2025072811393103000_4.2.e000309.47","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/qjmed\/hcab015","article-title":"Physical and mental health of older people while cocooning during the COVID-19 pandemic","volume":"114","author":"Bailey","year":"2021","journal-title":"QJM"},{"key":"2025072811393103000_4.2.e000309.48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15072"},{"key":"2025072811393103000_4.2.e000309.49","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108818","article-title":"Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine","volume":"230","author":"Garc\u00eda-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"2025072811393103000_4.2.e000309.50","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaneurol.2021.3287","article-title":"Rate of recurrent Guillain-Barr\u00e9 syndrome after mRNA COVID-19 vaccine BNT162b2","volume":"78","author":"Shapiro Ben David","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025072811393103000_4.2.e000309.51","article-title":"COVID-19 vaccination and Guillain-Barr\u00e9 syndrome: analyses using the National immunoglobulin database","author":"Keh","year":"2022","journal-title":"Brain"},{"key":"2025072811393103000_4.2.e000309.52","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"2025072811393103000_4.2.e000309.53","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(01)00019-6"},{"key":"2025072811393103000_4.2.e000309.54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2025072811393103000_4.2.e000309.55","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12470"},{"key":"2025072811393103000_4.2.e000309.56","doi-asserted-by":"crossref","unstructured":"Maurice C , Marcus B , Mason W . Guillain-Barre syndrome after treatment with dabrafenib for metastatic recurrent melaloma. P4. 232). AAN Enterprises 2015.","DOI":"10.1212\/WNL.84.14_supplement.P4.232"},{"key":"2025072811393103000_4.2.e000309.57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.153064"},{"key":"2025072811393103000_4.2.e000309.58","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","article-title":"Monoclonal Gammopathy-Associated peripheral neuropathy: diagnosis and management","volume":"92","author":"Chaudhry","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2025072811393103000_4.2.e000309.59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2022-000309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:39:41Z","timestamp":1753727981000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2022-000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,12]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bmjno-2022-000309"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2022-000309","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}